Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Immortalized cell lines play a pivotal role in the realm of cell biology, contributing significantly to the study of multicellular organisms and their biochemistry. These cell lines, characterized by cells that continuously divide without stopping or those manipulated to proliferate indefinitely, offer the advantage of being cultured over multiple generations. In the context of human hepatic cell lines, HepaRG and Hep G2 stand out as frequently utilized options for toxicity studies.
The increasing demand for immortalized cell lines is accompanied by a broadening array of applications, with a notable surge in adoption observed in stem cell therapy. Factors fueling this growth include heightened awareness regarding the utilization of cell lines in healthcare, expanding vaccine production, the growing application of cell lines in cancer therapy, and the integration of innovative technologies for cell line research. Despite these positive trends, challenges such as the high cost of equipment and the complexities associated with developing stable and authentic strains pose hindrances to the market's overall expansion.
As of 2017, the global immortalized cell line market was valued at USD 2,421.34 million, with projections indicating an anticipated rise to USD 4,105.62 million by 2023, reflecting a Compound Annual Growth Rate (CAGR) of 9.30% during the forecast period from 2018 to 2023. The Americas led the market in 2017, holding a share of 38.1%, followed by Europe with a share of 32.6%.
Examining the methods employed in immortalizing cell lines, virus induction claimed the largest market share at 39.9% in 2017. This technique's prominence is driven by its association with cancer research and the heightened demand for innovative drug discovery. The hTERT expression segment is expected to witness the highest CAGR of 9.94% during the forecast period.
Regarding applications, diagnostics represented the largest market share at 32.1% in 2017, with the increasing prevalence of chronic diseases like cancer and autoimmune disorders driving demand for rapid and effective therapeutics. The vaccine production segment is projected to experience the highest CAGR of 9.87% during the forecast period.
In terms of end-users, pharmaceutical and biopharmaceutical companies accounted for the largest market share at 54.7% in 2017. This dominance is attributed to growing awareness of monoclonal antibodies' application in cancer treatment and supportive government initiatives. The Contract Research Organization (CRO) segment is expected to witness the highest CAGR of 10.01% during the forecast period.
Regionally, the Americas maintained the largest market share at 38.1% in 2017, driven by continuous technological advancements and discoveries fostering the adoption of new bioproduction procedures. Europe is anticipated to exhibit the highest CAGR of 32.6% during the forecast period from 2018 to 2023.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | Â Â 4.90% (2022-2030) |
Immortalized Cell Line Market Highlights:
Global Immortalized Cell Line Market Overview
The Immortalized Cell Line Market Size was valued at USD 4.23 Billion in 2023. The Global Immortalized Cell Line industry is projected to grow from USD 4.51 Billion in 2024 to USD 7.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.67% during the forecast period (2024 - 2032). Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. These cell lines are expected to grow due to the rise in vaccine production and innovative technologies. Besides, the ability of cell line culture to provide more physiologically relevant information and more accurate data in-vitro tests has led cell line culture systems to become acceptable in comparison to media culture.
The increasing application in biotech and pharmaceutical companies and hospitals, a growing number of patients in need of organ transplantation, and the rise in the patient population affected by cancer are the major drivers propelling market growth. However, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination may hinder the growth of the market.
February 2024
For the first time ever, the revolutionary spontaneously immortalized bovine myoblast cell line known as PROFUSE-B8 has been formally introduced, and it is now available for licensing. In announcing its official debut, ProFuse Technology is glad to share the news. This recent achievement, which marks a significant milestone in the field of farmed meat, has resulted in the introduction of a paradigm shift in the efficient growth of muscle tissue that is rich in protein.
The PROFUSE-B8 cell line, which has been the subject of significant study and testing over the course of a full two-year period, provides cultured meat manufacturers with a solid and robust foundation for the establishment of scalable, repeatable, and cost-competitive production processes. This has been accomplished by testing and researching the cell line over the course of two years. It is important to note that B8 is able to do this without using any method that includes genetic alteration. This ensures that it is in complete accordance with the preferences and consent of customers.
Its revolutionary features are complimented by the fact that, when taken with the PROFUSE-S1 muscle differentiation media supplement, the synthesis of muscle tissue is speed up, which results in increased productivity in a shorter length of time. This is a significant advantage.
ProFuse Technology is 100% committed to advancing the cultured meat business by providing cutting-edge solutions for the production of muscle-related goods. This commitment is steadfast. At the same time, the company is making significant progress toward the development of other muscle production-optimized cell lines that are tailored to the unique requirements of chicken, hog, lamb, and fish for specialized purposes.
According to Dr. Tamar Eigler-Hirsh, Chief Technology Officer and Co-Founder of ProFuse Technology, in a statement, "We are thrilled to introduce PROFUSE-B8 as a transformative solution for the cultivated meat industry." "Our dedication to innovation and productivity is evident in the development of this breakthrough cell line, and we are confident it will shape the future of cell based protein production."
Immortalized Cell Line Market Trends
The increasing demand for organ donation due to scarcity in the availability of organs is driving the need for artificially created biological cells. For instance, according to the US Department of Health & Human Services Organ Procurement and Transplantation Network (OPTN), as of November 2016, 121,678 patients were waiting for a life-saving organ transplant. This rising demand for an organ transplant is expected to drive the growth of the market during the forecast period. Additionally, increasing application in biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer are likely to support market growth. On the other hand, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination is anticipated to hamper the market growth.
Immortalized Cell Line Market Segment Insights
The immortalized cell line market has been segmented into method, application, and end user.
Immortalized Cell Line Method Insights
Based on the method, the global market has been segmented into virus induction, hTERT expression, inactivation of tumor suppression genes, and others. The virus induction segment is further divided into EBV genes, SV40 T antigen, HPV-16 E6/6 gene, and others. The hTERT expression segment is sub-segmented into P53 and Myc T58A.
Immortalized Cell Line Application Insights
The immortalized cell line market, based on application, is segmented into diagnostics, drug discovery, vaccine production, tissue engineering and regenerative medicine, and others.
Immortalized Cell Line End User Insights
Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017.
Some of the key strategies followed by the players operating in the immortalized cell line market are innovation, product development, acquisition, and expansion.
Immortalized Clinell Line Market Regional Insights
The immortalized cell e market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is estimated to dominate the immortalized cell line market during the forecast period. This is attributed to an increase in the occurrence of cancer, the presence of well-established pharmaceutical and biotechnology industry, increasing awareness of immortalized cell lines, and strong research funding.
The European market for immortalized cell line is expected to be the second-largest during the forecast period. Increasing government support, well-developed technology, and rising cases of cancer are expected to boost the growth of the market in this region.
Asia-Pacific is estimated to be the fastest-growing market due to the increasing expenditure on healthcare by government and private sector companies. Moreover, the growing awareness about healthcare and large untapped patient population have led to the increased focus of key players on expansion in this region. Furthermore, the region accounted for a market share of 17.8% in 2017.
The immortalized cell line market in the Middle East & Africa is expected to hold the least market share.
Immortalized Cell Line Market Key Players
The prominent players in the immortalized cell line market are
- Thermo Fisher Scientific (US)
- ATCC (American Type Culture Collection Inc.) (US)
- Valneva (France),
- Sartorius AG (Germany)
- Lonza Group, AG (Switzerland)
- Merck KGaA (Germany)
- Selexis SA (Switzerland)
- WuXi App Tec (China)
- European Collection of Authenticated Cell Cultures (ECACC) (Europe)
- Corning Incorporated (US)
Immortalized Cell Line Industry Developments
In January 2024,Thermo Fisher Scientific Launched new Gibco™ Advanced DMEM/F12 media optimized for immortalized cell lines, claiming improved growth and performance.
In September2023,Lonza Group AG Announced partnership with CStone Pharmaceuticals to optimize and manufacture immortalized cell lines for CAR-T cell therapy development.
Immortalized Cell Line Market Segmentation
Immortalized Cell Line Method Outlook
- Virus Induction
- EBV genes
- SV40 T antigen
- HPV-16 E6/6 gene
- Others
- HTERT Expression
- P53
- Myc T58A
- Inactivation of Tumour Suppression Genes
- Others
Immortalized Cell Line Application Outlook
- Diagnostics
- Drug Discovery
- Vaccine Production
- Tissue Engineering and Regenerative Medicines
- Others
Immortalized Cell Line End User Outlook
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Research Laboratories
Immortalized Cell Line Regional Outlook
-
Americas
-
North America
-
US
-
Canada
-
South America
-
Europe
-
Western Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Rest of Western Europe
-
Eastern Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Rest of Asia-Pacific
-
Middle East & Africa
-
Middle East
-
Africa
Intended Audience
-
Research and development (R&D) companies
-
Government research institutes
-
Academic institutes and universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
